From patient deterioration early warning systems to managing long-term conditions, Sensyne Health is working with the NHS on pioneering AI solutions

Artificial Intelligence is heralding a new dawn in the way we diagnose, treat and manage disease


Lord Drayson seems a man on the move. As an amateur racing driver, it is perhaps an innate charateristic, and in the current debate around health data his foot is very much on the gas. I meet the former Labour

government science and defence minister shortly after he lays out a bold new vision for the NHS at FutureScot’s recent Digital Health & Care conference in Glasgow. Urbane and well-connected, Drayson is also a keen student of policy and how the arguments around big tech and health data are shaping up. For background, there is an in-

tensifying argument that the NHS needs to make much more use of a still largely untapped goldmine of data, which could herald a new dawn in the way we diagnose, treat and manage disease – not to mention save billions of pounds annually. Sensyne Health is at the forefront of this debate in the UK, and he very much wants pioneering healthcare artificial intelligence firms like his to be preferred over the tech giants of Silicon Valley, which he argues will extract value for the US economy and give very little back.

With post-Brexit trade deals

looming – and genuine concerns over whether the NHS is ‘on or off’ the table in any negotiations with the Trump administration – the whole spectre of a com- moditised NHS is, like politics in general, deeply divisive. But that is why Drayson believes his radical new scheme – in which value created from his AI products could be reinvested back into the health system, keeping the benefits firmly rooted in the UK – would be a more welcome prospect than allowing multina- tional tech companies to access health records in order to develop new medicines, and then charge the NHS to use them.

Based in Oxford – in the heart of UK science’s so-called ‘golden tri- angle’ – Drayson’s company, Sen- syne Health, was only floated last year (at a market value of £225m) but has already developed a raft of innovative AI tools in such fields as acute medicine, lung and heart disease and diabetes. But rather than cream off the rewards solely for shareholders, the com- pany’s business model is founded on the premise that the NHS should benefit financially from its data resources: in exchange


for ethical access to anonymized patient data, NHS Trusts receive an equity stake in the company as well as a share of royalties from any medical discoveries resulting from the AI analysis. Paul Drayson, who has a PhD

in robotics, argues that it has also become very difficult for an organisation the size of the NHS to clean and manage its informa- tion in one coherent dataset. And at a time when resources are so stretched, a data-led revolution might just be the shot in the arm that the NHS needs. “Remember that patient re-

cords used to be at the end of the hospital bed, filled in with paper and pen,” Drayson says. “Well, now – and increasingly – that in- formation is stored on computer and as medicines become more complex, and as databases have got larger and larger, the analysis of that data is really beyond hu- man understanding.” He adds: “So, we need to use

new tools and machine learning and artificial intelligence to be able to make sense of this data and drive new insights, which al- low us to improve that care. And we need to do that in a way which is consistent with the values of our NHS and that’s why Sensyne

Health was created: for profit, we are a publicly-listed company that works in partnership with the National Health Service to create a social impact and recycle a share of the financial returns generated from this type of work back into the NHS.”

Sensyne Health has struck up contracts with a number of NHS trusts in England – working with the likes of NHS South Warwick- shire, NHS Oxford University Hospitals, NHS Chelsea & West- minster Hospital and the Royal Berkshire NHS Foundation Trust; the contracts are non-exclusive because the company does not believe in monopolising NHS data for its own ends. Sensyne also has strategic research agreements pending and Drayson’s speech at the FutureScot conference is a clear sign it wants to bring some its work to the Scottish market. With creeping marketisation

arguably an even bigger concern north of the Border, Drayson places great emphasis on the fact his company seeks only access to ‘anonymised data’, as trust levels remain critical when it comes to privacy and confidentiality. He even went so far as to commission research into his proposition, and

Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36